Daily non-political popular news in brief.

Tamoxifen yields long-term reduction in breast cancer risk

Tamoxifen offers long-term benefits for breast cancer prevention among women at high risk of the disease, according to two randomized, blinded clinical trials in the February 21 Journal of the National Cancer Institute. The trials found that the breast cancer risk reduction persists long after women stop taking tamoxifen.

Read more »

Keywords: tamoxifen, yields, long-term, reduction, breast, cancer, risk, yield, long, term

« Previous | Next »

Similar news on "Tamoxifen yields long-term reduction in breast cancer risk":

1. Chemotherapy and tamoxifen reduce risk of second breast cancer
   12-25-2007 · EurekAlert!
   Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online Dec. 25 in the Journal of the National Cancer Institute. The risk reduction persisted for at least 10 and 5 years, respectively.
   Similar news · Read more »
   
2. Breastfeeding reduces risk of breast cancer for women who delay childbirth
   04-16-2007 · EurekAlert!
   Breastfeeding can offset the increased risk of invasive breast cancer for women who had their first full-term pregnancy after the age of 25, a study led by researchers at the University of Southern California suggests. The findings of the study were presented at a news conference on Monday, April 16 at the 2007 annual meeting of the American Association for Cancer Research held in Los Angeles.
   Similar news · Read more »
   
3. Long-term use of adult-strength aspirin linked to a moderate decreased cancer risk
   04-17-2007 · EurekAlert!
   A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.
   Similar news · Read more »
   
4. Herceptin does not increase heart failure in patients long-term
   06-03-2007 · EurekAlert!
   Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
   Similar news · Read more »
   
5. USC-led study suggests exercise reduces risk of developing invasive breast cancer
   02-26-2007 · EurekAlert!
   Significant findings have emerged from the California Teachers Study (CTS) that suggest long-term recreational physical activity plays a protective role against invasive and in situ breast cancer.
   Similar news · Read more »
   
6. Early switch to an aromatase inhibitor increases survival
   02-12-2007 · EurekAlert!
   For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes -- a significant risk associated with tamoxifen.
   Similar news · Read more »
   
7. Radiation therapy reduces cancer recurrence in older breast cancer patients
   01-22-2007 · EurekAlert!
   Radiation therapy after lumpectomy and five years of treatment with the drug tamoxifen can dramatically reduce the risk of both cancer recurrence and new tumors in older women with early breast cancer, according to researchers from Wake Forest University School of Medicine and colleagues.
   Similar news · Read more »
   
8. Breast cancer survival rates improved by novel drug sequence, say researchers
   02-12-2007 · EurekAlert!
   Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
   Similar news · Read more »
   
9. Other highlights in the May 2 JNCI
   05-01-2007 · EurekAlert!
   Also in the May 2 JNCI is a follow-up to the Italian Randomized Tamoxifen Trial, a study on treating breast cancer patients with three HER inhibitor drugs, an increase in survival rates for indolent lymphoma patients using a chemotherapy-rituximab combination, and new lung cancer risk prediction models.
   Similar news · Read more »
   
10. Researchers identify key gene that may be a marker of breast cancer metastasis
    04-18-2007 · EurekAlert!
    Researchers at Fox Chase Cancer Center have identified an important gene involved in the spread of breast cancer that has developed resistance to long-term estrogen deprivation. The gene may prove to be a useful marker for predicting which patients have the greatest risk of breast cancer recurrence so their doctors can offer the most appropriate treatment plan.
    Similar news · Read more »